The FDA Advisory Committee Just Voted on Six Compounded Peptides. Here Is What Actually Changed.

Breaking — PCAC voted on seven peptides. Six passed. One did not.

On July 23 and 24, 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) completed a two-day session at the agency’s White Oak campus in Silver Spring, Maryland, voting on seven peptide bulk drug substances for potential inclusion on the Section 503A Bulks List. Six were recommended for inclusion. One — DSIP (emideltide) — was voted against. Every one of the six affirmative votes went against FDA career staff briefing documents, which had recommended against adding any of the seven substances to the list (FDA meeting page; The Hill’s day-two summary).

The specific votes are worth knowing in detail because the margins were narrow — and because the fine print matters more than the headline. On Day 1 (July 23), the committee voted to recommend BPC-157, KPV, TB-500, and MOTS-c. On Day 2 (July 24), the committee voted to recommend Epitalon and Semax, and voted against DSIP.

This is genuinely significant for compounding pharmacies and clinicians who work with peptide therapies. It is also being widely misread. Below, an evidence-graded walk-through of what the vote is, what it is not, and what it means for our patients at Pravida.

The votes, line by line

Each substance was actually voted on twice — once for the free-base form and once for the acetate salt — but the pattern above summarizes the composite committee position on each substance per publicly available reporting (FDA meeting agenda; Becker’s Hospital Review coverage).

What the vote actually does — and what it does not do

The framing that keeps getting missed: PCAC votes are advisory and non-binding. The committee provides scientific, technical, and medical input to the FDA. The agency is not required to follow its recommendations. Even where the FDA agrees with a favorable committee vote, the substance still has to be added to the 503A Bulks List through formal notice-and-comment rulemaking — a process that routinely takes twelve to eighteen months. The Orrick regulatory brief lays out the three-step regulatory pathway explicitly: Category 2 removal, PCAC recommendation, and Category 1 placement via rulemaking.

What did not change: nothing about the legal status of any of these peptides changed on July 24. None of the six recommended peptides became FDA-approved drugs. None of them can legally be sold as finished pharmaceutical products. And the DSIP “no” vote does not re-impose the Category 2 restriction that was lifted for all seven back on April 23, 2026.

What may change, eventually: if the FDA agrees with PCAC’s six affirmative recommendations and initiates rulemaking, licensed 503A compounding pharmacies could eventually be permitted to prepare those substances against an individual patient prescription under the standard compounding framework (USP quality standards, licensed provider evaluation, patient-specific prescription). That is a real change in the regulatory pathway, but the realistic horizon is late 2026 at the earliest and more likely 2027 per most legal analyses.

The honest caveat: FDA career staff explicitly recommended against adding any of the seven substances to the list, citing inadequate physical and chemical characterization, insufficient human clinical trial evidence, safety signals in FAERS adverse event reports, and World Anti-Doping Agency prohibited-substance status for two (MOTS-c and TB-500). The PCAC vote went the other way — but the underlying evidence gaps flagged by career staff have not disappeared (Orrick brief; Becker’s summary).

What happens next

The FDA will now review the committee’s recommendations alongside the full scientific record, public comments (~1,860 filed by docket FDA-2025-N-6895 close), and other regulatory considerations before making a final decision. That is not a rubber stamp — PCAC recommendations are advisory, and the agency can and sometimes does depart from them.

If the FDA agrees and moves forward, it would publish a proposed rule in the Federal Register, open a public comment period, respond to comments, and then publish a final rule adding the substance to the Category 1 side of the 503A Bulks List. Only at that point does anything become legally compoundable under the routine 503A framework. Under normal timelines that whole process runs twelve to eighteen months from start to finish (Orrick brief).

A second PCAC session is expected before the end of February 2027 to review five additional peptides that were also removed from Category 2 in April 2026 — including LL-37, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF. That session is worth watching for anyone thinking about how the broader regulatory picture will settle (Becker’s).

What this means for patients

The direct answer: for patients currently working with a licensed longevity or regenerative medicine clinic and a licensed 503A pharmacy on individually prescribed peptide therapy, nothing about your care changed on July 24. Legal access continues under the same physician-prescribed, pharmacy-compounded framework that has been operating since the April 2026 Category 2 removal.

The honest read on the six “yes” votes: if the FDA follows PCAC and initiates rulemaking on BPC-157, KPV, TB-500, MOTS-c, Epitalon, or Semax, the medium-term outcome is that quality standards, sourcing consistency, and prescriber accountability improve. That is a good thing. A regulated compounding pathway with USP quality standards is materially safer than the current environment in which some of these compounds are moving through research-use-only channels with heavy-metal contamination, mislabeled contents, and adverse event signals in samples pulled from the compounding stream (FDA career-staff briefing concerns, per Orrick).

The DSIP framing: the “no” vote on DSIP is not a ban. DSIP came off the Category 2 list in April 2026 along with the other six, and a PCAC vote against inclusion does not re-impose that restriction. What the vote does mean is that a formal compounding pathway will likely not open for DSIP through this round of rulemaking. The modern human evidence base for DSIP as a sleep treatment is thin and dated — small studies from the 1970s and 1980s with mixed results, and no contemporary randomized clinical program — and the committee vote appears to reflect that.

The framing we use with our patients: we treat these committee votes the way we treat any advisory-committee news — a signal about where regulatory thinking is moving, not a change in what is safe or evidence-supported today. A PCAC “yes” on BPC-157 does not make BPC-157 a proven therapy for tendon injury. It means a regulated pathway may eventually exist for compounding it. The clinical question — whether the peptide is right for a specific patient given the actual quality of the evidence — is unchanged.

The honest caveat: the six affirmative votes went 8-6 or 7-5 or 7-4. Those are close margins on substances that FDA career staff, the American Pharmacists Association, and multiple patient-safety groups all recommended against. That closeness matters. Peptides remain an area where the marketing has out-run the evidence, and the vote does not close that gap.

How we approach peptide therapy at Pravida Health

At Pravida Health in Atlanta, peptide therapy is a tool we discuss with patients when the clinical case supports it and the risk-benefit calculus is honest. We work only with licensed 503A pharmacies that meet USP quality standards. We do not sell peptides. We do not use social-media-driven “stacks” that combine six peptides at once for undefined outcomes.

For every peptide we consider prescribing, we ask three questions:

• Is there human clinical evidence for the specific indication, dose, and duration in front of us — or only mouse data and mechanistic plausibility?
• Is the sourcing pathway a licensed 503A compounding pharmacy with USP quality standards, or a research-use-only vendor?
• Does the patient understand that off-label use of a compounded peptide is not the same as an FDA-approved therapy?

For patients in our Foundation, Pinnacle, and Executive Health memberships who are candidates for peptide therapy, we integrate that discussion with laboratory baselines, symptom tracking, side-effect review, and the same evidence-graded framework we apply to any other longevity intervention. The July 2026 PCAC vote may eventually open a cleaner regulatory pathway for six of these substances — but at our clinic on 1801 Peachtree St NE, Ste 150, the underlying clinical bar has not moved. The evidence has to earn its place.

A PCAC vote is a signal, not a verdict. The clinical question — is this the right therapy for this patient, given the actual quality of the evidence — is unchanged.

Dr. Trevor Turner is a physician and co-founder of Pravida Health, a regenerative medicine and longevity practice in Atlanta, Georgia. He writes about the intersection of clinical medicine, emerging performance and longevity interventions, and how physicians should weigh dose, safety, and evidence quality before recommending a new protocol to patients.